Business Description
Summit Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US86627T1088
Share Class Description:
MEX:SMMT: Ordinary SharesTotal Employee Number:
265Description
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 33.88 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -56.3 | |||||
3-Year EPS without NRI Growth Rate | -10.1 | |||||
3-Year FCF Growth Rate | -25.7 | |||||
3-Year Book Growth Rate | 12.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 17.74 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 0.31 | |||||
9-Day RSI | 4.82 | |||||
14-Day RSI | 13.81 | |||||
6-1 Month Momentum % | 3.25 | |||||
12-1 Month Momentum % | -31.79 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.96 | |||||
Quick Ratio | 6.96 | |||||
Cash Ratio | 6.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -54.3 | |||||
Shareholder Yield % | -0.03 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -187.21 | |||||
ROA % | -156.39 | |||||
ROIC % | -2206.26 | |||||
3-Year ROIIC % | 407.31 | |||||
ROC (Joel Greenblatt) % | -5671.62 | |||||
ROCE % | -184.24 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 21.76 | |||||
Price-to-Tangible-Book | 21.88 | |||||
EV-to-EBIT | -15.13 | |||||
EV-to-EBITDA | -15.14 | |||||
EV-to-Forward-Revenue | 246.13 | |||||
EV-to-FCF | -28.52 | |||||
| Price-to-Net-Current-Asset-Value | 23.04 | |||||
| Price-to-Net-Cash | 24 | |||||
Earnings Yield (Greenblatt) % | -6.61 | |||||
FCF Yield % | -3.34 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Summit Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | |||
| EPS (TTM) (MXN) | -20.176 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 62.81 | ||
| 14-Day RSI | 13.81 | ||
| 14-Day ATR (MXN) | 0.03909 | ||
| 20-Day SMA (MXN) | 290.12 | ||
| 12-1 Month Momentum % | -31.79 | ||
| 52-Week Range (MXN) | 281 - 430 | ||
| Shares Outstanding (Mil) | 797.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Summit Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Summit Therapeutics Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-23 16:30 | In 168 days | ||
| Annual report for 2026 | 2027-02-23 | In 167 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-23 | In 167 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-20 08:00 | In 42 days | ||
| Third quarter earnings results for 2026 | 2026-10-20 | In 41 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-23 16:30 | 290.12 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-07-23 | 290.12 (+0.00%) | ||
| General meeting for 2026 | 2026-06-10 08:30 | 290.12 (+0.00%) | ||
| 47th Annual Goldman Sachs Global Healthcare Conference | 2026-06-08 10:00 | 290.12 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-06-01 07:00 | 290.12 (+0.00%) |
Show
Entries
Summit Therapeutics Inc Frequently Asked Questions
What is Summit Therapeutics Inc(MEX:SMMT)'s stock price today?
The current price of MEX:SMMT is MXN290.12. The 52 week high of MEX:SMMT is MXN430.00 and 52 week low is MXN281.00.
When is next earnings date of Summit Therapeutics Inc(MEX:SMMT)?
The next earnings date of Summit Therapeutics Inc(MEX:SMMT) is 2026-10-20 Est..
Does Summit Therapeutics Inc(MEX:SMMT) pay dividends? If so, how much?
Summit Therapeutics Inc(MEX:SMMT) does not pay dividend.
Press Release
Articles on Summit Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers